MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
MaaT034, the first product from MaaT Pharma’s MET-C platform is a ground-breaking full ecosystem synthetic microbiota product, developed in combination with immune checkpoint inhibitors to improve treatment efficacy in large market solid tumor indications.
- MaaT034, the first product from MaaT Pharma’s MET-C platform is a ground-breaking full ecosystem synthetic microbiota product, developed in combination with immune checkpoint inhibitors to improve treatment efficacy in large market solid tumor indications.
- The MET-C platform enables MaaT Pharma to produce microbiome therapies at a large-scale to meet the needs of larger market indications.
- The data published represents significant advancements in understanding the mechanism of action (MoA) of co-cultured microbiome therapies developed by MaaT Pharma, marking a major step towards clinical evaluation.
- These findings support the role of MaaT034 in gut barrier repair and in T cell reactivation either in combination with Nivolumab (anti-PD1) or with Atezolizumab (anti-PD-L1).